CALL FOR ABSTRACTS
Submission deadline: January 31, 2019
International presenters will be notified by
January 2, 2019 to assist with making
travel arrangements.

Memorial Sloan Kettering Cancer Center
is pleased to present the third annual

CLINICAL APPLICATION OF
CAR T CELLS

MARCH 14-15, 2019
ZUCKERMAN RESEARCH CENTER
NEW YORK CITY

MSK COURSE DIRECTOR
Prasad S. Adusumilli, MD, FACS, FCCP

MSK COURSE CO-DIRECTORS
Renier J. Brentjens, MD, PhD
Michel Sadelain, MD, PhD

This activity has been approved for
AMA PRA Category 1 Credit™.
Chimeric antigen receptor (CAR) T-cell (“Living Drug”) immunotherapy is showing promising results in the treatment of cancers. There are nine ongoing clinical trials (Phase I & II) at Memorial Sloan Kettering (MSK) and more are on track to be initiated next year. Over the years, MSK has accumulated a breadth of knowledge about developing and translating these clinical trials from bench to bedside and back to bench – constructing, manufacturing and obtaining FDA approvals for clinical grade CARs and vectors, developing universal algorithms across multiple CAR T-cell clinical trials for the treatment and management of complications, and conducting world-class correlative science. MSK faculty, along with national and international experts, will discuss the clinical and translational aspects of cell therapies (CARs, TCRs, NKs), both for hematologic malignancies and solid tumors.

**MAIN SESSIONS TOPICS**
- Building a clinical CAR T-cell program
- Mechanisms of Relapse in CD19 CAR T-cell therapies
- Solid tumor cell therapy clinical trials
- Toxicity management in clinic
- Next-gen CARs for hematological malignancies
- Off-the shelf cell therapies
- Biomarkers and novel assays for cell therapy monitoring
- Manufacturing processes for cell engineering
- Navigating the IP and licensing landscape

**BREAKOUT SESSIONS TOPICS**
- Meet the experts session
- Case studies & Rapid-fire presentations
- ABC of Cell Therapy for paramedical staff
- Novel gene engineering in cell therapies
- Operational infrastructure of commercial cell therapies

The target audience includes medical oncologists and oncology fellows, basic scientists, research fellows, nurses, clinical trial research staff, immunologists, and surgeons with an interest in tumor immunology and immunotherapy.

**CALL FOR ABSTRACTS**
Participants are invited to submit an abstract for presentation at the course. Abstracts for the poster session will be selected on the basis of scientific merit and content quality. Submission deadline: January 31, 2019. International presenters will be notified by January 2, 2019 to assist with making travel arrangements.

[mskcc.org/cartcell](http://mskcc.org/cartcell)